TMS Co., Ltd.
Stock Price Chart
2026/07/10 UpdatedPrice Trend
2026/07/10 UpdatedPrice & Trading Details
2026/07/10 UpdatedPRICE
TRADING
Financial Performance
2026/07/05 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | |
|---|---|
| Income Statement | |
| Revenue | ¥1,947M |
| Gross Profit | - |
| Operating Income | ¥1,136M |
| Pretax Income | ¥1,136M |
| Net Income | ¥1,077M |
| EPS | ¥53.36 |
| Operating Margin | 58.34% |
| Balance Sheet | |
| Total Assets | ¥2,740M |
| Total Equity | ¥2,453M |
| Total Liabilities | ¥287M |
| Cash | ¥2,598M |
| Interest-bearing Debt | - |
| Equity Ratio | 89.53% |
| D/E Ratio | 0.00 |
| Cash Flow | |
| Operating CF | ¥1,262M |
| Investing CF | -¥17M |
| Financing CF | ¥246M |
| Free CF | ¥1,253M |
| Efficiency | |
| ROE | 43.90% |
| ROA | 39.30% |
Latest IR Information
Latest News (5 items)
Company Information
About
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. In addition, the company has a collaboration with Hokkaido University to evaluate the potential of the drug candidate compounds as novel drugs. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.
